Modulation of Protein S-nitrosylation Signaling as a Potential Therapeutic Breakthrough in Rheumatoid Arthritis
调节蛋白质 S-亚硝基化信号传导是类风湿关节炎的潜在治疗突破
基本信息
- 批准号:10817318
- 负责人:
- 金额:$ 27.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-20 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AftercareAnimalsAnti-Inflammatory AgentsAntioxidantsArthritisAutoantibodiesAutoimmuneAutoimmune DiseasesAutoimmune ResponsesAutoimmunityB-LymphocytesBindingBiological AssayBiological AvailabilityBiological MarkersBiological ProductsBone remodelingCartilageCellsChronicClinicalClinical TrialsCollagenCollagen ArthritisDiseaseDisease ProgressionDoseEGF geneEnzyme InhibitionEnzyme-Linked Immunosorbent AssayEnzymesExtracellular MatrixFemaleFinancial costFormulationGenerationsGenesGrantHourHumanHyperplasiaImmuneImmune responseImmunofluorescence ImmunologicImmunosuppressive AgentsImpairmentInfiltrationInflammationInflammation MediatorsInflammatoryInterleukin-6Interstitial CollagenaseIntraperitoneal InjectionsInvadedIsoprostanesJointsKneeKnee jointLeadLipidsMacrophageMalondialdehydeMatrix MetalloproteinasesMeasuresMediatingMedicalMinorityMusNitrogenOralOxidantsOxidative StressOxidoreductaseOxygenPainPathogenesisPathologyPatientsPharmaceutical PreparationsPhasePlasmaPolysaccharidesProductionProtein SProteinsProteoglycanQuality of lifeReactive Oxygen SpeciesResolutionReverse Transcriptase Polymerase Chain ReactionRheumatoid ArthritisRiskS-NitrosoglutathioneSafetySerum amyloid A proteinSeverity of illnessSignal PathwaySignal TransductionSignaling ProteinStainsSymptomsSystemT cell infiltrationTNF geneTNFSF11 geneTherapeuticTherapeutic InterventionTissuesToxic effectVEGFA geneVascular Cell Adhesion Molecule-1Workabsorptionarthropathiesbonechronic autoimmune diseasecytokinedisabilityefficacy evaluationimmune cell infiltrateimprovedin vivoinhibitorjoint destructionjoint inflammationlead candidatemalemitochondrial dysfunctionmouse modelnovelnovel therapeutic interventionoxidationoxidative damagepre-clinicalpreservationrestorationside effectsmall molecule inhibitortherapeutic target
项目摘要
PROJECT SUMMARY
Rheumatoid arthritis (RA) is a prevalent autoimmune disease of the joints that involves autoimmunity, B and T
cell infiltration, mitochondrial dysfunction, ECM degradation, oxidative stress and inflammation, that ultimately
lead to cartilage destruction and bone reabsorption. Oxidative stress is a hallmark of RA: reactive oxygen species
(ROS) inflict direct damage via the oxidation of proteins, lipids, and glycans, including oxidation of cartilage
proteoglycans, and act as secondary messengers to activate regulators of inflammatory genes, further
exacerbating the inflammation/oxidative damage-immune response cycle. Critically, innate anti-oxidant systems
are impaired in RA; however, increases in protein S-nitrosylation have been shown to protect from oxidant and
inflammatory damage. SAJE Pharma [DBA: GSNO Therapeutics] is developing a novel therapeutic approach
for RA treatment that reestablishes healthy antioxidative and anti-inflammatory pathway signaling by increasing
protein S-nitrosylation on relevant proteins by inhibiting the enzyme S-nitrosoglutathione reductase (GSNOR).
GSNOR activity is elevated in many inflammatory and oxidative stress related diseases resulting in abnormal,
disease producing protein S-nitrosylation. GSNOR inhibition by SAJE Pharma's GTI-891.1 increases GSNO
levels and reestablishes homeostatic protein S-nitrosylation levels, without toxicity or off-target effects. GSNOR
is the major reductase of GSNO, the body's largest reservoir of nitrosylating activity; therefore, it is an attractive
therapeutic target for increasing protective S-nitrosylating activity for antioxidative and anti-inflammatory
signaling in RA, while reducing oxidative and nitrosative damage. While existing therapies help manage patient
pain and symptoms, only a minority can slow disease progression, and all carry risks for serious side effects.
GTI-891.1 has excellent safety profiles and no known off-target effects inhibiting many pathophysiological drivers
of RA. Preliminary in vivo work demonstrates that GTI-891.1 by intraperitoneal injection reduces RA disease
progression, improves clinical scores, reduces immune cell infiltration and inflammation in joints, and reduces
pro-inflammatory cytokines in the collagen-induced arthritis (CIA) mouse model of RA. This proposal aims to
extend those studies and evaluate GTI-891.1’s oral activity in the CIA mouse model of RA via oral dosing to
assess its therapeutic potential by quantifying disease pathology improvements after treatment with GTI-891.1
in an experimental autoimmune CIA mouse model of RA. By reducing pro-inflammatory cytokine levels,
infiltration of T and inflammatory B cells, GSNOR inhibition by SAJE's GTI-891.1 presents a promising,
multifaced approach for RA management and treatment. The work in this grant will validate oral GTI-891.1
mediated GSNOR inhibition as a viable therapeutic intervention to mitigate RA progression and fulfill an unmet
clinical need for reducing clinical signs of RA and improving patient quality of life.
项目摘要
类风湿性关节炎(Rheumatoid arthritis,RA)是一种常见的自身免疫性关节疾病,涉及自身免疫、B和T
细胞浸润,线粒体功能障碍,ECM降解,氧化应激和炎症,最终
导致软骨破坏和骨重吸收。氧化应激是RA的标志:活性氧
(ROS)通过蛋白质、脂质和聚糖的氧化(包括软骨的氧化)造成直接损伤
蛋白聚糖,并作为第二信使激活炎症基因的调节因子,
加剧炎症/氧化损伤-免疫应答循环。关键是,先天抗氧化系统
在RA中受损;然而,蛋白质S-亚硝基化的增加已被证明可以保护免受氧化剂的影响,
炎性损伤SAJE Pharma [DBA:GSNO Therapeutics]正在开发一种新的治疗方法
对于RA治疗,通过增加抗氧化和抗炎途径信号传导,
通过抑制酶S-亚硝基谷胱甘肽还原酶(GSNOR),对相关蛋白质进行蛋白质S-亚硝基化。
GSNOR活性在许多炎症和氧化应激相关疾病中升高,
致病蛋白S-亚硝基化。SAJE Pharma的GTI-891.1的GSNOR抑制增加了GSNO
水平和重建稳态蛋白S-亚硝基化水平,没有毒性或脱靶效应。GSNOR
是GSNO的主要还原酶,GSNO是体内最大的亚硝基化活性库;因此,它是一种有吸引力的
用于增加抗氧化和抗炎的保护性S-亚硝基化活性的治疗靶点
信号,同时减少氧化和亚硝化损伤。虽然现有疗法有助于管理患者
疼痛和症状,只有少数可以减缓疾病的进展,所有的风险,严重的副作用。
GTI-891.1具有良好的安全性,并且没有已知的脱靶效应,可抑制许多病理生理驱动因素
的RA。初步的体内研究表明,腹膜内注射GTI-891.1可减少RA疾病
进展,改善临床评分,减少关节中的免疫细胞浸润和炎症,
促炎细胞因子在RA的胶原诱导的关节炎(CIA)小鼠模型中。这项建议旨在
扩展这些研究,并通过口服给药评价GTI-891.1在RA CIA小鼠模型中的口服活性,
通过量化GTI-891.1治疗后的疾病病理学改善来评估其治疗潜力。
在RA的实验性自身免疫性CIA小鼠模型中。通过降低促炎细胞因子水平,
T和炎性B细胞的浸润,SAJE的GTI-891.1对GSNOR的抑制呈现出有希望的,
RA管理和治疗的多方面方法。这项资助的工作将验证口头GTI-891。
介导的GSNOR抑制作为一种可行的治疗干预措施,以缓解RA进展并实现未满足的
减少RA临床体征和改善患者生活质量的临床需求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthews Ogden Bradley其他文献
Matthews Ogden Bradley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 27.97万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 27.97万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 27.97万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 27.97万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 27.97万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 27.97万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 27.97万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 27.97万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 27.97万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 27.97万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)